Skip to main content
Quest Diagnostics

Development of a High-Throughput NGS Workflow for SARS-CoV-2 Whole-Genome Sequencing

CROI 2022 (Conference on Retroviruses and Opportunistic Infections)
Denver, CO, Feb 12 -16, 2022

Poster presentation: Development of a High-Throughput NGS Workflow for SARS-CoV-2 Whole-Genome Sequencing

Authors: Rosenthal SH, Gerasimova A,  Ruiz-Vega R, Livingston K, Kagan RM, Liu Y, Anderson B,  Owen R, Bernstein L,  Smolgovsky A, Xu D, Chen R, Grupe A, Tanpaiboon P, Lacbawan F

Specialties: Genetics, Infectious Disease, COVID-19

Related content

Publication
Development and validation of a high throughput SARS-CoV-2 whole genome sequencing workflow in a clinical laboratory
Conference Presentation
Correlates of immunity in SARS-CoV-2 post-vaccine infectious in the Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) Study

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.